<DOC>
	<DOCNO>NCT01609127</DOCNO>
	<brief_summary>This study conduct compare efficacy safety tesetaxel administer every 3 week 21-day cycle , tesetaxel administer weekly 3 consecutive week 28-day cycle , capecitabine administer twice daily 14 consecutive day 21-day cycle .</brief_summary>
	<brief_title>Tesetaxel Every 3 Weeks vs Weekly v Capecitabine 1st-line Therapy Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Key inclusion criterion : 1 . Female 2 . At least 18 year age 3 . Locally advanced nonresectable metastatic breast cancer 4 . HER2 negative disease 5 . Measurable disease per revise RECIST , Version 1.1 6 . Eastern Cooperative Oncology Group performance status 0 1 7 . Chemotherapy naïve , OR 1 prior chemotherapy regimen neoadjuvant adjuvant setting provide patient diseasefree interval ≥ 12 month end chemotherapy . If neoadjuvant adjuvant chemotherapy include taxane , ≥ 2 year must pass since treatment end . 8 . Documented disease recurrence progression 9 . Adequate bone marrow , hepatic , renal function 10 . Ability swallow oral soliddosage form medication 11 . Written inform consent Key exclusion criterion : 1 . Known metastasis central nervous system 2 . Other cancer within precede 5 year curatively treat basal squamous cell carcinoma skin carcinoma cervix situ 3 . Significant medical disease breast cancer 4 . Presence neuropathy &gt; Grade 1 ( NCI CTC ) 5 . History hypersensitivity taxane capecitabine , fluoropyrimidine agent , ingredient 6 . History severe unexpected reaction fluoropyrimidine therapy 7 . Need continue regularlytaken medication potent inhibitor inducer CYP3A pathway 8 . Less 2 week since use medication ingestion agent , beverage , food potent inhibitor inducer CYP3A pathway 9 . Known dihydropyrimidine dehydrogenase deficiency 10 . Pregnancy lactation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>